Delivery Order SPE2DB22D3004-SPE2DB25FRP68
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,088.36 to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Mounjaro 12.5 mg/0.5 mL pen injectors (0.5 mL). This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, designated SPE2DX and valued at $999.99 million through December 2026. The product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $2,448.81 to AmerisourceBergen Drug Corp for Mounjaro 10 mg/0.5 mL pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order represents a non-competitive award under a larger contract vehicle and will be fulfilled at the contractor's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control in patients with type 2...
- The Defense Logistics Agency awarded a delivery order valued at $2,192.78 to AmerisourceBergen Drug Corp for the supply of Mounjaro 12.5 mg/0.5 mL pens on July 23, 2025, with an ultimate completion date of July 24, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,088.36 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Mounjaro 15 mg/0.5 mL pens. This competitively awarded, firm fixed-price contract, which is non-set-aside, is scheduled for completion by July 28, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control in patients with type 2 diabetes. This delivery order...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,761.93 for Mounjaro 5 mg/0.5 ml pens on July 24, 2025, with an ultimate completion date of July 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a $2,496.33 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 12.5 mg/0.5 ml pens on July 22, 2025, with an ultimate completion date of July 23, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively awarded with no set-aside designation, and...
- The Defense Logistics Agency awarded a delivery order valued at $4,156.21 to AmerisourceBergen Drug Corp for the supply of Mounjaro 2.5 mg/0.5 mL pens (0.5 mL units) on July 25, 2025, with a completion date of July 28, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion vehicle running through December...
- The Defense Logistics Agency awarded a $5,981.34 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Mounjaro 5 mg/0.5 ml pens. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by July 24, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control in patients with type 2 diabetes. This delivery order represents a single...
- The Defense Logistics Agency awarded a delivery order valued at $3,157.74 to AmerisourceBergen Drug Corp for the supply of Mounjaro 2.5 mg/0.5 mL pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a diabetes management medication, consistent with AmerisourceBergen's extensive portfolio of...
- The Defense Logistics Agency awarded a delivery order valued at $45,830.70 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pen injectors (0.5 mL units). This firm fixed-price delivery order, awarded on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a non-competitive award under an existing contract vehicle. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FRP68Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,992.99 to AmerisourceBergen Drug Corp for the supply of Mounjaro 2.5 mg/0.5 mL pens on July 23, 2025, with completion scheduled for July 24, 2025. This is a firm fixed-price delivery order issued under a non-set-aside procurement, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a brand-name pharmaceutical product used in the treatment of Type 2 diabetes, reflecting the Defense Logistics Agency's ongoing medical supply requirements for military healthcare systems. This delivery order represents a child contract executed under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting the Defense Health Agency and military healthcare operations globally. The company's federal contract portfolio demonstrates consistent capability in delivering pharmaceuticals and medical supplies through competitively awarded contracts, positioning it as a significant provider within the DLA's pharmaceutical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.0k | 7/23/25 |